ArticleThe clinical respiratory journal2026
Therapeutic Targets for Lung Squamous Cell Carcinoma: Proteome-Wide Mendelian Randomization and Potential Drug Prediction.
Article in The clinical respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung squamous cell carcinoma (LUSC) is one of the most prevalent subtypes of lung cancer, accounting for approximately 25%. Mendelian randomization (MR) analysis of plasma proteins can identify potential drug targets for LUSC.
methodsWe obtained genetic instruments for plasma proteins from a GWAS by Sun BB et al. conducted on 3301 healthy adults. GWAS summary statistics of LUSC were from ILCCO. We conducted a two-sample MR analysis to investigate the causal relationships between plasma proteins and the risk to LUSC. Colocalization analysis was used to test whether two traits share the same causal variables. Survival analysis based on potential proteins was conducted using transcriptomic data from TCGA database to determine whether gene expression levels are associated with the prognosis of LUSC patients. Moreover, predictions of potential drug ligands and molecular dockings were performed to evaluate the pharmaceutical properties of the target genes.
resultsProteome-wide MR analysis identified three proteins (MICB, SPINK2, TXNDC11) that showed a strong association with decreased risk of LUSC after FDR correction. Increased levels of MICB [OR(95% CI) = 0.72(0.63, 0.83); p = 3.90E-06], SPINK2 [OR (95% CI) = 0.74 (0.66, 0.84); p = 1.25E-06], TXNDC11 [OR (95% CI) = 0.63(0.51, 0.78); p = 2.69E-05] per SD decreased the risk of LUSC specifically. Sensitivity analysis revealed that there was no significant heterogeneity, pleiotropy, or reverse causality between these proteins and LUSC. Colocalization analysis indicated that three proteins shared the same variants with LUSC. Survival analysis showed that upregulation of SPINK2 was associated with a favorable prognosis in LUSC patients, while MICB and TXNDC11 were not. The expression of MICB, SPINK2, TXNDC11 was found to be potentially affected by specific substances, and our molecular docking showed a stable binding between SPINK2 and danazol, suggesting its potential as a drug target.
conclusionThis study identified SPINK2 causally associated with the risk and prognosis of LUSC, which is a promising target for LUSC. The drug prediction we performed illustrated the medicinal potential of SPINK2, and the high binding activity of molecular docking indicated its strong potential as a drug target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.